PDSB beat EPS expectations by 33.29%
Aug 21, 2024, 9:33 AM
0.00%
What does PDSB do
PDS Biotechnology Corp., based in Princeton, New Jersey, develops immunotherapies for various cancers, including a lead candidate, PDS0101, targeting HPV16-associated cancers with its Versamune technology. The company, which went public in 2015, employs 26 people and is advancing a pipeline of therapies using Versamune and Infectimune platforms.
PDS Biotechnology (PDSB) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, PDS Biotechnology's actual EPS was -$0.23, beating the estimate of -$0.34 per share, resulting in a 33.29% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.